Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories

Next-generation sequencing (NGS) to identify pathogenic mutations is an integral part of acute myeloid leukemia (AML) therapeutic decision-making. The concordance in identifying pathogenic mutations among different NGS platforms at different diagnostic laboratories has been studied in solid tumors b...

Descripción completa

Detalles Bibliográficos
Autores principales: Borate, Uma, Yang, Fei, Press, Richard, Ruppert, Amy S., Jones, Dan, Caruthers, Sean, Zhao, Weiqiang, Vergilio, Jo-Anne, Pavlick, Dean C., Juckett, Luke, Norris, Brianna, Bucy, Taylor, Burd, Amy, Stein, Eytan M., Patel, Prapti, Baer, Maria R., Stock, Wendy, Schiller, Gary, Blum, William, Kovacsovics, Tibor, Litzow, Mark, Foran, James, Heerema, Nyla A., Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley, Stefanos, Mona, Druker, Brian, Byrd, John C., Levine, Ross L., Mims, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582272/
https://www.ncbi.nlm.nih.gov/pubmed/37459200
http://dx.doi.org/10.1182/bloodadvances.2022009008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582272/
https://www.ncbi.nlm.nih.gov/pubmed/37459200
http://dx.doi.org/10.1182/bloodadvances.2022009008

Ejemplares similares